Ariad Pharmaceuticals Inc

Type: Company
Name: Ariad Pharmaceuticals Inc
First reported Apr 16 2014 - Updated Apr 16 2014 - 3 reports

Ariad Pharmaceuticals : to Webcast Conference Call on First Quarter 2014 Financial Results

ARIADPharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it willreport its first quarter 2014 financial results on Wednesday, May 7,2014, before the market opens. Following the announcement, at 8:30 a.m.Eastern Time, company management will host ... [Published 4 Traders - Apr 16 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

After Yesterday's Decline of 1.67%, Ariad Pharmaceuticals Offers Investors Better Value

(Comtex SmarTrend(R)) Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.85 to a high of $7.33. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $6.89 on volume of 10.8 million ... [Published Individual.com - Apr 14 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

ARIAD appoints senior vice president and chief business officer

ARIAD Pharmaceuticals, Inc., a developer of new medicines for treatment of cancer, has appointed Hugh Cole as senior vice president and chief business officer. Mr Cole will be responsible for global business and corporate development, licensing and strategic ... [Published Individual.com - Apr 08 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

3 Reasons an Ariad Pharmaceuticals Buyout Is Unlikely

Following its late 2012 approval by the Food and Drug Administration to treat two rare types of leukemia, Ariad Pharmaceuticals ' ( NASDAQ: ARIA     ) shareholders have experienced the full roller-coaster ride of unwavering success and unfathomable ... [Published Motley Fool Discussion Boards - Apr 04 2014]
First reported Apr 03 2014 - Updated Apr 04 2014 - 2 reports

MassBio panel tackles drug industrys bad reputation

At the panel titled, "The Image Problem of the BioPharma Industry," panelists included (from the left) Lori Gorski of Genzyme; Maria Cantor at Ariad Pharmaceuticals; Lisa Adler of Millennium; ... ... [Published Big News Network - Apr 04 2014]
First reported Apr 02 2014 - Updated Apr 03 2014 - 2 reports

Ariad Pharmaceuticals Given Average Rating of “Hold” by Brokerages (NASDAQ:ARIA)

Ariad Pharmaceuticals (NASDAQ:ARIA) has received an average rating of “Hold” from the twenty-four analysts that are presently covering the stock, . Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating ... [Published American Banking News - Forex - Apr 03 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 5 reports

ARIAD Appoints Hugh Cole as Chief Business Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate ... [Published Citybizlist - Apr 02 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 4 reports

Technical Pointers on Top Gainers -- Research on ARIAD Pharma, Arotech,

Restoration Hardware Holdings, and Sprouts Farmers Market03/31 11:52 CDT Restoration Hardware Holdings, and Sprouts Farmers MarketEditor Note: For more information about this release, please scroll to bottom LONDON, March 31, 2014LONDON, March 31, ... [Published Finwin - Mar 31 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 3 reports

Ariad Pharmaceuticals (ARIA) Jumps on More Buyout Rumors

Shares of small-cap pharma Ariad Pharmaceuticals ( ARIA ) were trading higher on Friday after rumors were started by British paper The Daily Mail that Jazz Pharmaceuticals ( JAZZ ) was interested in acquiring the company at $20 a share.Ariad, already ... [Published Equities.com - Mar 28 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 2 reports

MARKET REPORT: Drug giants fail to swallow Ariad Pharmaceuticals

As shares of UK pharmaceutical giants GlaxoSmithKline shed 9.5p to 1,614p and Shire declined 20p to 3,035p, dealers heard that both had lost out in the auction for Massachusetts-based Ariad Pharmaceuticals.They were strongly tipped, along with Eli Lilly, ... [Published NewsRT.co.uk - Mar 27 2014]
First reported Mar 24 2014 - Updated Mar 25 2014 - 3 reports

Why Now Is The Time To Buy Ariad Pharmaceuticals

Ariad Pharmaceuticals, Inc (ARIA) has given many the ride of their life over the past six months. ARIA fell nearly 90% stemming back to October 2013 when Iclusig (AKA Ponatinib) was pulled from the U.S. market due to "an increased frequency of blood clots ... [Published Citybizlist - Mar 25 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 4 reports

Ariad Launches Phase 2 Lung Cancer Trial

Ariad Pharmaceuticals Inc. announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. The ALTA (ALK in Lung Cancer ... [Published Drug Discovery and Development - Mar 24 2014]

Quotes

...and director of successful cancer drug development programs," commented Jerry McMahon, Ph D , President and Chief Executive Officer of Kolltan. "I anticipate his insight will be critical as Kolltan further advances its clinical and late-stage preclinical pipeline of promising product candidates. In addition, Mr. Slattery's successful investment career and knowledge of the biotech markets will be of great value to the Board."
...Berger. "He will be integral in seeking business and corporate development opportunities for ARIAD, including a commercial partnership for Iclusig® in Japan, as well as helping to further maximize our oncology pipeline."
...find people who have that breadth and depth of knowledge," not to mention the personality and professionalism that's required for the job, he says. "That quality where everyone perks up when they speak, or when they enter a room they have this presence -- I can't teach those things."

More Content

All (360) | News (272) | Reports (0) | Blogs (67) | Audio/Video (0) | Fact Sheets (1) | Press Releases (20)
sort by: Date | Relevance
Kolltan Pharmaceuticals Appoints Daniel Vlock t... [Published Citybizlist - Apr 16 2014]
Acute Myelocytic Leukemia (AML, Acute Myeloblas... [Published SBWire - Apr 16 2014]
Ariad Pharmaceuticals : to Webcast Conference C... [Published 4 Traders - Apr 16 2014]
ARIAD to Webcast Conference Call on First Quart... [Published BusinessWeek - Apr 16 2014]
ARIAD to Webcast Conference Call on First Quart... [Published Business Wire Health News - Apr 16 2014]
Uptrend Call Working As Ariad Pharmaceuticals S... [Published Individual.com - Apr 15 2014]
After Yesterday's Decline of 1.67%, Ariad Pharm... [Published Individual.com - Apr 14 2014]
FDA Approves Novartis' ALK Inhibitor! Maybe...R... [Published Lebanon Daily News - Apr 11 2014]
New Report Available: Acute Lymphocytic Leukemi... [Published SBWire - Apr 11 2014]
ARIAD Announces Appointment of Hugh Cole, Senio... [Published NewsRX - Apr 11 2014]
Clinical Trial Results and Initiation, Endowmen... [Published Financial Services - Apr 11 2014]
Buyers Accumulate Shares of Ariad Pharmaceutica... [Published Individual.com - Apr 09 2014]
Ariad Pharmaceuticals is Among the Companies in... [Published Individual.com - Apr 09 2014]
Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) Rides... [Published Live Trading News - Apr 08 2014]
ARIAD appoints senior vice president and chief ... [Published Individual.com - Apr 08 2014]
Ariad Pharmaceuticals Has Returned 101.6% Since... [Published Individual.com - Apr 08 2014]
TrialNetworks Wins Disruptive Technology and In... [Published PRWeb - Apr 08 2014]
Mallinckrodt to Buy Drugmaker Questcor Pharmace... [Published Accesswire - Apr 08 2014]
Hugh Cole leaves Shire for Ariad [Published PMLive - Apr 08 2014]
Hottest Healthcare Stocks Now – QCOR SEM KND PBYI [Published InvestorPlace.com - Apr 07 2014]
IT Salary Survey 2014: Who's hot, who's not [Published Computerworld Norge - Apr 07 2014]
ARIAD Taps New Chief Business Officer [Published Individual.com - Apr 07 2014]
3 Reasons an Ariad Pharmaceuticals Buyout Is Un... [Published Motley Fool Discussion Boards - Apr 04 2014]
Hottest Healthcare Stocks Now – MYL ALGN CLVS MYGN [Published InvestorPlace.com - Apr 04 2014]
Novartis gets new head of Japanese business ami... [Published FierceBiotech - Apr 04 2014]
MassBio panel tackles drug industrys bad reputa... [Published Big News Network - Apr 04 2014]
Insider Selling: Timothy P. Clackson Sells 6,50... [Published American Banking News - Apr 04 2014]
Ariad Pharmaceuticals SVP Sells $34,893 in Stoc... [Published American Banking News - Apr 04 2014]
Ariad Pharmaceuticals VP Sells $19,728 in Stock... [Published American Banking News - Apr 04 2014]
Ariad Pharmaceuticals CMO Sells $27,914 in Stoc... [Published American Banking News - Apr 04 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ARIAD to Webcast Conference Call on First Quart... [Published Business Wire Health News - Apr 16 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern ...
ARIAD Announces Appointment of Hugh Cole, Senio... [Published Business Wire Photo/Multimedia News - Apr 02 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate ...
ARIAD Announces Appointment of Hugh Cole, Senio... [Published Business Wire Health News - Apr 02 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate ...
ARIAD Announces Appointment of Hugh Cole, Senio... [Published Business Wire News with Multimedia - Apr 02 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate ...
ARIAD Announces Initiation of Pivotal Phase 2 A... [Published Business Wire Health News - Mar 24 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Clinical Trial Results and Initiation, Endowmen... [Published Financial Services - Apr 11 2014]
Technical Pointers on Top Gainers -- Research o... [Published Financial Services - Mar 31 2014]
Insider Trading Research -- Alerts for Ariad Ph... [Published Financial Services - Mar 25 2014]
New Appointments, Contract Extensions, Share Pr... [Published Financial Services - Mar 05 2014]
FDA Approvals, Stock Price Movements, and Acqui... [Published Financial Services - Dec 25 2013]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.